Liothyronine Shortage: What Providers and Prescribers Need to Know in 2026

The thyroid medication landscape shifted significantly in 2025-2026. FDA enforcement actions against unapproved desiccated thyroid extract (DTE) products, combined with persistent availability challenges for levothyroxine at certain strengths, have put synthetic T3 therapy — liothyronine — in a new spotlight. Providers prescribing liothyronine need to be informed about current supply dynamics, prescribing considerations, and patient management strategies.

Current Supply Status: What Providers Need to Know

As of 2026, liothyronine oral tablets are not on the FDA's official national drug shortage list. Manufacturers continue to produce the drug, and multiple generic manufacturers supply the U.S. market. That said, providers should be aware of real-world availability dynamics:

Chain pharmacies: Stock liothyronine in limited quantities, particularly the 5 mcg strength. Patients refilling prescriptions may encounter temporary out-of-stock situations.

Independent pharmacies: Generally better positioned to source liothyronine and may have stronger distributor relationships.

Brand-name Cytomel (Pfizer): Less commonly stocked than generic. If your patient requires brand-name, direct them to independent pharmacies or mail-order.

Increasing demand pressure: The FDA's August 2025 actions against DTE products are driving more prescribers toward synthetic T3 prescriptions. This increased demand has the potential to create localized supply gaps.

The NDT Transition and Its Impact on Liothyronine Prescribing

The FDA's August 6, 2025 announcement that desiccated thyroid extract products do not have approved biologics license applications (BLAs) has created significant pressure on providers to transition patients off Armour Thyroid, NP Thyroid, and other DTE medications within a 12-month window. This has several implications for liothyronine prescribing:

Increased T4/T3 combination prescribing: Many patients transitioned from Armour Thyroid will be started on levothyroxine + liothyronine combination therapy to approximate the T4/T3 content they were receiving from DTE products.

Higher volume liothyronine prescriptions: Practices with large integrative or functional medicine patient populations may see a meaningful increase in liothyronine prescriptions as DTE patients transition.

Patient expectation management: Patients used to the fixed T4:T3 ratio of DTE products (roughly 4:1 in Armour Thyroid) need to understand that synthetic T4/T3 combination therapy allows more precise dose titration but may require adjustment periods.

Clinical Considerations When Prescribing Liothyronine

Liothyronine has a narrow therapeutic index and several clinical considerations that providers should keep in mind:

Rapid onset and short half-life: T3 has a half-life of approximately 2.5 days and onset of action within hours. T3 peaks rapidly after each dose, which can produce symptoms of thyrotoxicosis if the dose is too high — particularly cardiovascular effects such as palpitations and arrhythmias.

Cardiovascular caution: In elderly patients and those with coronary artery disease, start at 5 mcg/day and increase by 5 mcg every 2 weeks. Atrial fibrillation is the most common arrhythmia associated with thyroid hormone overtreatment.

Anticoagulant interactions: Liothyronine increases the response to warfarin and other oral anticoagulants. Monitor INR closely when initiating, changing, or discontinuing liothyronine in anticoagulated patients.

Bone density: Thyroid hormone overreplacement can decrease bone mineral density, particularly in post-menopausal women. Use the minimum effective dose.

Monitoring: TSH alone is not a reliable monitoring tool when prescribing combination T4/T3 therapy. Free T3 levels should be monitored along with clinical assessment.

Proactive Patient Management Strategies

Providers can reduce pharmacy-related disruptions for liothyronine patients with a few proactive steps:

Prescribe 90-day supplies when clinically appropriate and payer-permitted, to reduce refill frequency.

Indicate "substitution permitted" on prescriptions to allow generic dispensing, which is far more widely available than brand-name Cytomel.

Document backup medication plans in patient charts in case liothyronine becomes temporarily unavailable (e.g., dose adjustment protocol, compounding pharmacy option).

Direct patients to medfinder for Providers to assist with real-time stock checks across nearby pharmacies.

medfinder for Providers: Supporting Your Patients' Access

medfinder offers a provider platform that can help your patients find their liothyronine prescription in stock at pharmacies near them — without calling each pharmacy. This is particularly valuable for patients with mobility limitations, those in rural areas, or patients who are new to the medication and don't know which pharmacies in their area stock it.

The Bottom Line for Providers

Liothyronine is not in a formal national shortage in 2026, but providers should be aware of growing demand pressure, localized availability gaps, and the downstream effects of the DTE regulatory upheaval. Proactive prescribing strategies and patient education can prevent gaps in therapy. For a complete guide to helping your patients find liothyronine in stock, see: How to help your patients find liothyronine in stock.